Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study
ABSTRACT Introduction This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization (NCT04355793). Methods Patients received ruxolitinib 5 mg twice da...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.70050 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Introduction This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization (NCT04355793). Methods Patients received ruxolitinib 5 mg twice daily (preferred regimen when tolerated) or once daily for ≤ 14 days, or until determination of no clinical benefit was made. Outcomes were clinical status, physician‐assessed clinical benefit, and serious adverse event (SAE) incidence. Results Of 312 patients, 45.5% achieved ≥ 1‐point clinical status improvement. Physician‐assessed clinical benefit was reported in 42.6% of evaluable patients. SAEs occurred in 42.9%, with 2.6% experiencing an SAE suspected to be ruxolitinib related. Conclusions Overall, some hospitalized patients with COVID‐19–associated cytokine storm who received ruxolitinib experienced clinical status improvement; ruxolitinib was well tolerated. Trial Registration ClinicalTrials.gov identifier: NCT04355793 |
|---|---|
| ISSN: | 1752-6981 1752-699X |